Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration） approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018. The assay is for qualitative detection of 96 hotspot mutations/fusions in EGFR, KRAS, BRAF, NRAS, HER2, PIK3CA, ALK, ROS1 and RET genes, intended to be used to help clinicians identify multi-targets status for NSCLC patients.
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
Next
Subscribe
to our
newsletter